Idioma:

Failure of 17-hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double-blind, randomized clinical trial

Combs, C. Andrew, MD, PhD ; Garite, Thomas, MD ; Maurel, Kimberly, MSN ; Das, Anita, PhD ; Porto, Manuel, MD

American journal of obstetrics and gynecology, 2010-09, Vol.203 (3), p.248.e1-248.e9 [Periódico revisado por pares]

New York, NY: Elsevier Inc

Texto completo disponível

Citações Citado por

Enviar para

Título:
Failure of 17-hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double-blind, randomized clinical trial
Autor: Combs, C. Andrew, MD, PhD ; Garite, Thomas, MD ; Maurel, Kimberly, MSN ; Das, Anita, PhD ; Porto, Manuel, MD
Assuntos: 17-alpha-Hydroxyprogesterone - therapeutic use ; 17-hydroxyprogesterone ; Abortion, Spontaneous - epidemiology ; Adult ; Biological and medical sciences ; Diseases of mother, fetus and pregnancy ; Double-Blind Method ; Female ; Fetal Death - epidemiology ; Gestational Age ; Gynecology. Andrology. Obstetrics ; Humans ; Infant, Newborn ; Infant, Newborn, Diseases - epidemiology ; Medical sciences ; Obstetrics and Gynecology ; Pregnancy ; Pregnancy Complications - epidemiology ; Pregnancy, High-Risk ; Pregnancy, Multiple ; Pregnancy. Fetus. Placenta ; Premature Birth - prevention & control ; preterm delivery ; progesterone ; triplet pregnancy ; Triplets
É parte de: American journal of obstetrics and gynecology, 2010-09, Vol.203 (3), p.248.e1-248.e9
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-News-1
ObjectType-Feature-3
content type line 23
Descrição: Objective To test whether 17 alpha-hydroxyprogesterone caproate (17P) will reduce neonatal morbidity by increasing gestational age at delivery in triplet pregnancies. Study Design Double-blind, randomized clinical trial. Mothers carrying trichorionic-triamniotic triplets were randomly assigned (in a 2:1 ratio) to weekly injections of 250 mg of 17P or placebo, starting at 16-22 weeks and continued until 34 weeks. Primary outcome was composite neonatal morbidity. Results Fifty-six women were randomized to 17P and 25 to placebo. Composite neonatal morbidity occurred with similar frequency in the 17P and placebo groups (38% vs 41%, respectively; P = .71). Mean gestational age at delivery was not affected by 17P (31.9 vs 31.8 weeks; P = .36). There were 13 midtrimester fetal losses with 17P vs none with placebo ( P < .02). Conclusion In triplet pregnancy, prophylactic treatment with 17P did not reduce neonatal morbidity or prolong gestation but was associated with increased midtrimester fetal loss.
Editor: New York, NY: Elsevier Inc
Idioma: Inglês

Links

Voltar para lista de resultados

Anterior Resultado 2 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Failure of 17-hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double-blind, randomized clinical trial

Combs, C. Andrew, MD, PhD ; Garite, Thomas, MD ; Maurel, Kimberly, MSN ; Das, Anita, PhD ; Porto, Manuel, MD

New York, NY: Elsevier Inc

Buscando em bases de dados remotas. Favor aguardar.